Evofem Biosciences Balance Sheet Health
Financial Health criteria checks 0/6
Evofem Biosciences has a total shareholder equity of $-64.6M and total debt of $43.4M, which brings its debt-to-equity ratio to -67.1%. Its total assets and total liabilities are $8.6M and $73.2M respectively.
Key information
-67.1%
Debt to equity ratio
US$43.40m
Debt
| Interest coverage ratio | n/a |
| Cash | n/a |
| Equity | -US$64.63m |
| Total liabilities | US$73.18m |
| Total assets | US$8.55m |
Recent financial health updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Financial Position Analysis
Short Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: EVFM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: EVFM has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: EVFM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if EVFM has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EVFM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.